Stem Cell Therapy

The FDA approved axatilimab-csfr for treating chronic graft-versus-host disease after at least two lines of systemic therapy in adults and certain children.

A study presented at the ASCO 2024 Annual Meeting found that a multimodal intervention improved sexual function and quality of life in HSCT survivors. Learn how.

Data show revumenib monotherapy induced measurable residual disease–negative remissions in heavily pretreated patients with difficult-to-treat acute leukemias.

Phase 2 data show that axatilimab yielded a high response in heavily pretreated chronic graft-versus-host disease and “may represent a new therapeutic strategy.”

Daratumumab added to VRd outperformed VRd alone in treating adults with newly diagnosed multiple myeloma eligible for autologous stem cell transplantation.

A quadruplet therapy boosts MRD negativity in multiple myeloma, prompting discussion over MRD’s use as a surrogate endpoint at the 2023 ASH annual meeting.

New data show that MRD in the peripheral blood after chemotherapy in NPM1-mutated AML predicted whether stem cell transplant in first remission improved survival.

Long-term follow-up data suggest that sorafenib maintenance after transplantation improves overall survival in patients with FLT3-ILD AML, but key questions remain.

Maintenance ibrutinib is effective for patients with treatment-naïve mantle cell lymphoma after induction chemotherapy, according to a new, four-year study.

Michael Wang, MD, and Bob Figlin, MD, discuss promising new findings in MCL, as well as how to apply the “explosion” of new options in practice.

New data show improved survival with quizartinib added to standard therapy and stem cell transplant in patients with FLT3-mutated AML.

Experts at SOHO 2023 debated whether patients with AML should proceed directly to transplantation or undergo a regimen to secure remission beforehand.